ID: ALA2086892

Max Phase: Preclinical

Molecular Formula: C23H29N3O4S2

Molecular Weight: 475.64

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(Cn2ccnc2)c1

Standard InChI:  InChI=1S/C23H29N3O4S2/c1-4-5-11-30-23(27)25-32(28,29)22-21(14-20(31-22)12-17(2)3)19-8-6-7-18(13-19)15-26-10-9-24-16-26/h6-10,13-14,16-17H,4-5,11-12,15H2,1-3H3,(H,25,27)

Standard InChI Key:  ZWDDUNMMFDVANI-UHFFFAOYSA-N

Associated Targets(Human)

Angiotensin II type 2 (AT-2) receptor 2549 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Type-1 angiotensin II receptor 5176 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 2B6 1338 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 2C9 32119 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 2D6 33882 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 3A4 53859 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

NG108-15 132 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Type-1A angiotensin II receptor 520 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 475.64Molecular Weight (Monoisotopic): 475.1599AlogP: 5.07#Rotatable Bonds: 10
Polar Surface Area: 90.29Molecular Species: ACIDHBA: 7HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 4.61CX Basic pKa: 6.47CX LogP: 4.58CX LogD: 4.78
Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.41Np Likeness Score: -0.98

References

1. Murugaiah AM, Wu X, Wallinder C, Mahalingam AK, Wan Y, Sköld C, Botros M, Guimond MO, Joshi A, Nyberg F, Gallo-Payet N, Hallberg A, Alterman M..  (2012)  From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists.,  55  (5): [PMID:22248302] [10.1021/jm2015099]
2. Guimond MO, Hallberg M, Gallo-Payet N, Wallinder C..  (2014)  Saralasin and Sarile Are AT2 Receptor Agonists.,  (10): [PMID:25313325] [10.1021/ml500278g]
3. Wallinder C, Sköld C, Botros M, Guimond MO, Hallberg M, Gallo-Payet N, Karlén A, Alterman M..  (2015)  Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.,  (2): [PMID:25699147] [10.1021/ml500427r]
4. Sallander J, Wallinder C, Hallberg A, Åqvist J, Gutiérrez-de-Terán H..  (2016)  Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.,  26  (4): [PMID:26810314] [10.1016/j.bmcl.2015.10.084]
5. Wannberg J, Isaksson R, Bremberg U, Backlund M, Sävmarker J, Hallberg M, Larhed M..  (2018)  A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes.,  28  (3): [PMID:29279275] [10.1016/j.bmcl.2017.11.042]
6. Wannberg J,Gising J,Lindman J,Salander J,Gutiérrez-de-Terán H,Ablahad H,Hamid S,Grönbladh A,Spizzo I,Gaspari TA,Widdop RE,Hallberg A,Backlund M,Leśniak A,Hallberg M,Larhed M.  (2021)  N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands.,  29  [PMID:33309749] [10.1016/j.bmc.2020.115859]
7. Gopalan G, Palo-Nieto C, Petersen NN, Hallberg M, Larhed M..  (2022)  Angiotensin II AT2 receptor ligands with phenylthiazole scaffolds.,  65  [PMID:35550979] [10.1016/j.bmc.2022.116790]

Source